Clinical Trial Update: Trial of Two Adagrasib Dosing Regimens in NSCLC With KRAS G12C Mutation (KRYSTAL 21) [Phase 2]

View source ↗

Summary

Phase 2 trial KRYSTAL 21 is evaluating two adagrasib dosing regimens in non-small cell lung cancer with KRAS G12C mutation; the study is active but not currentl…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Krazati (adagrasib) (adagrasib)

Snippet

Sponsor: Mirati Therapeutics Inc. | Conditions: Advanced Cancer, Metastatic Cancer | Phase 2 | Status: ACTIVE_NOT_RECRUITING